Sun Says Specialty Drug Spend Will Check Profit Growth
Sun Pharmaceutical Industries has cautioned that investments to ramp up its specialty business will “check” profit growth near-term, as a one-off charge pushed down its fourth-quarter net income by more than 50%.
You may also be interested in...
With no news on the progress of a board-level strategic review on offer, investors reacted negatively to Mylan falling short of consensus sales figures. This took the firm's share price to its lowest level for more than five years.
Teva, along with Mylan, Pfizer, Sandoz and 16 other generics manufacturers, have found themselves in the spotlight after a further multi-state US lawsuit has accused them of participating in a price-fixing conspiracy.
Sun’s MD Dilip Shanghvi made the rather frank admission during the firm’s third-quarter earnings call, maintaining that generics is nevertheless an “interesting” business for the Indian major. In light of this outlook, Sun has continued its policy of withdrawing what it feels are “unviable” ANDAs from under FDA review.